AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
bromfenac 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-inflammatory agents, ibufenac derivatives | 401 | 91714-94-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID). The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2, prostaglandins are mediators of certain kinds of intraocular inflammation.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.28 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 67 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.11 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.60 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.188 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.778 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 97.499 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.959 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 1.390 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 2.790 | % | High | 1 |
| herg | hERG pIC50 | 4.470 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 3.228 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.090 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 1.670 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GSK3B,IKBKB,ITK,JAK2,MAP2K6,MAP3K7,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 34 | |||
| kinase-selectivity-class | ACVR2B,AXL,EIF2AK3,GRK2,MAP2K6 | 5 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 2.805 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 10.765 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 3.510 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.303 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 2.440 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.079 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 3.199 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 77.890 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 1.300 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 944.061 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 24, 2005 | FDA | BAUSCH AND LOMB INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Corneal oedema | 116.83 | 29.79 | 21 | 1404 | 1880 | 90625142 |
| Cataract | 104.21 | 29.79 | 40 | 1385 | 72052 | 90554970 |
| Endophthalmitis | 97.94 | 29.79 | 21 | 1404 | 4664 | 90622358 |
| Hypopyon | 82.43 | 29.79 | 14 | 1411 | 900 | 90626122 |
| Toxic anterior segment syndrome | 81.95 | 29.79 | 16 | 1409 | 2234 | 90624788 |
| Eye irritation | 75.77 | 29.79 | 26 | 1399 | 33952 | 90593070 |
| Eye pain | 72.77 | 29.79 | 27 | 1398 | 44141 | 90582881 |
| Corneal opacity | 62.14 | 29.79 | 11 | 1414 | 900 | 90626122 |
| Product packaging quantity issue | 62.07 | 29.79 | 12 | 1413 | 1590 | 90625432 |
| Visual acuity reduced | 56.42 | 29.79 | 19 | 1406 | 23391 | 90603631 |
| Corneal disorder | 53.28 | 29.79 | 11 | 1414 | 2031 | 90624991 |
| Ulcerative keratitis | 52.88 | 29.79 | 12 | 1413 | 3441 | 90623581 |
| Corneal infiltrates | 48.07 | 29.79 | 7 | 1418 | 164 | 90626858 |
| Corneal perforation | 45.80 | 29.79 | 8 | 1417 | 605 | 90626417 |
| Visual impairment | 44.50 | 29.79 | 27 | 1398 | 132338 | 90494684 |
| Anterior chamber cell | 44.34 | 29.79 | 8 | 1417 | 728 | 90626294 |
| Punctate keratitis | 43.72 | 29.79 | 8 | 1417 | 788 | 90626234 |
| Vision blurred | 40.97 | 29.79 | 24 | 1401 | 110269 | 90516753 |
| Ocular hyperaemia | 39.09 | 29.79 | 16 | 1409 | 33782 | 90593240 |
| Product colour issue | 37.35 | 29.79 | 7 | 1418 | 785 | 90626237 |
| Intraocular pressure increased | 35.11 | 29.79 | 10 | 1415 | 7083 | 90619939 |
| Eye inflammation | 34.10 | 29.79 | 10 | 1415 | 7841 | 90619181 |
| Lacrimation increased | 31.93 | 29.79 | 13 | 1412 | 27049 | 90599973 |
| Photophobia | 31.35 | 29.79 | 12 | 1413 | 21257 | 90605765 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cataract | 83.68 | 38.55 | 28 | 722 | 30576 | 42590009 |
| Hypopyon | 59.76 | 38.55 | 10 | 740 | 525 | 42620060 |
| Endophthalmitis | 58.87 | 38.55 | 14 | 736 | 4419 | 42616166 |
| Eye pain | 56.23 | 38.55 | 18 | 732 | 17012 | 42603573 |
| Toxic anterior segment syndrome | 56.10 | 38.55 | 11 | 739 | 1405 | 42619180 |
| Intraocular pressure increased | 53.69 | 38.55 | 14 | 736 | 6419 | 42614166 |
| Corneal oedema | 49.15 | 38.55 | 10 | 740 | 1538 | 42619047 |
| Visual acuity reduced | 47.64 | 38.55 | 16 | 734 | 17534 | 42603051 |
| Ulcerative keratitis | 46.17 | 38.55 | 10 | 740 | 2078 | 42618507 |
| Corneal infiltrates | 39.41 | 38.55 | 6 | 744 | 171 | 42620414 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Endophthalmitis | 161.69 | 28.05 | 35 | 1703 | 8152 | 110579409 |
| Corneal oedema | 155.90 | 28.05 | 29 | 1709 | 3144 | 110584417 |
| Hypopyon | 136.43 | 28.05 | 23 | 1715 | 1417 | 110586144 |
| Toxic anterior segment syndrome | 134.71 | 28.05 | 26 | 1712 | 3428 | 110584133 |
| Eye pain | 102.76 | 28.05 | 36 | 1702 | 50063 | 110537498 |
| Cataract | 100.34 | 28.05 | 40 | 1698 | 79445 | 110508116 |
| Corneal opacity | 91.32 | 28.05 | 16 | 1722 | 1235 | 110586326 |
| Corneal infiltrates | 79.77 | 28.05 | 12 | 1726 | 354 | 110587207 |
| Ulcerative keratitis | 75.38 | 28.05 | 17 | 1721 | 4749 | 110582812 |
| Corneal disorder | 73.71 | 28.05 | 15 | 1723 | 2582 | 110584979 |
| Visual acuity reduced | 69.31 | 28.05 | 24 | 1714 | 32149 | 110555412 |
| Intraocular pressure increased | 61.45 | 28.05 | 17 | 1721 | 10859 | 110576702 |
| Anterior chamber cell | 58.92 | 28.05 | 11 | 1727 | 1210 | 110586351 |
| Ocular hyperaemia | 57.36 | 28.05 | 22 | 1716 | 39264 | 110548297 |
| Corneal perforation | 55.05 | 28.05 | 10 | 1728 | 946 | 110586615 |
| Lacrimation increased | 54.93 | 28.05 | 20 | 1718 | 30930 | 110556631 |
| Eye irritation | 53.41 | 28.05 | 20 | 1718 | 33432 | 110554129 |
| Visual impairment | 51.94 | 28.05 | 30 | 1708 | 134398 | 110453163 |
| Vision blurred | 45.11 | 28.05 | 27 | 1711 | 128995 | 110458566 |
| Punctate keratitis | 40.41 | 28.05 | 8 | 1730 | 1196 | 110586365 |
| Metamorphopsia | 37.98 | 28.05 | 8 | 1730 | 1625 | 110585936 |
| Eye inflammation | 36.86 | 28.05 | 11 | 1727 | 9160 | 110578401 |
| Eye oedema | 34.39 | 28.05 | 8 | 1730 | 2554 | 110585007 |
| Cystoid macular oedema | 33.69 | 28.05 | 8 | 1730 | 2792 | 110584769 |
| Anterior chamber fibrin | 30.76 | 28.05 | 5 | 1733 | 245 | 110587316 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01BC11 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Antiinflammatory agents, non-steroids |
| FDA CS | M0001335 | Anti-Inflammatory Agents, Non-Steroidal |
| FDA MoA | N0000000160 | Cyclooxygenase Inhibitors |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| FDA EPC | N0000175722 | Nonsteroidal Anti-inflammatory Drug |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
Related Drugs by ATC class:
S01BC Antiinflammatory agents, non-steroids 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pain | indication | 22253000 | |
| Postoperative Ocular Pain | indication | ||
| Post-Op Ocular Inflammation | indication | ||
| Rheumatoid arthritis | contraindication | 69896004 | DOID:7148 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Red eye | contraindication | 75705005 | |
| Epithelial Keratopathy | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.32 | acidic |
| pKa2 | 3.17 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 0.075% ACID | BROMSITE | SUN PHARM | N206911 | April 8, 2016 | RX | SOLUTION/DROPS | OPHTHALMIC | RE50218 | March 5, 2029 | TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY |
| EQ 0.07% ACID | PROLENSA | BAUSCH AND LOMB | N203168 | April 5, 2013 | RX | SOLUTION/DROPS | OPHTHALMIC | 9517220 | Nov. 11, 2033 | TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 8.40 | WOMBAT-PK | CHEMBL | |||
| Prostaglandin G/H synthase 1 | Enzyme | INHIBITOR | IC50 | 8.29 | WOMBAT-PK | CHEMBL | |||
| Cyclooxygenase | Enzyme | IC50 | 7.10 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D07541 | KEGG_DRUG |
| 120638-55-3 | SECONDARY_CAS_RN |
| 1375918 | RXNORM |
| C0054094 | UMLSCUI |
| CHEBI:240107 | CHEBI |
| 27R | PDB_CHEM_ID |
| CHEMBL1077 | ChEMBL_ID |
| CHEMBL3181947 | ChEMBL_ID |
| DB00963 | DRUGBANK_ID |
| C053083 | MESH_SUPPLEMENTAL_RECORD_UI |
| 60726 | PUBCHEM_CID |
| 7131 | IUPHAR_LIGAND_ID |
| 5892 | INN_ID |
| 864P0921DW | UNII |
| 181436 | MMSL |
| 200626 | MMSL |
| 31652 | MMSL |
| 34500 | MMSL |
| 35934 | MMSL |
| 4299 | MMSL |
| 67379 | MMSL |
| d04150 | MMSL |
| 108520008 | SNOMEDCT_US |
| 108521007 | SNOMEDCT_US |
| 417155005 | SNOMEDCT_US |
| 725788000 | SNOMEDCT_US |
| 4021048 | VANDF |
| 4024075 | VANDF |
| 006757 | NDDF |
| 006758 | NDDF |
| 864P0921DW | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Prolensa | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-602 | SOLUTION/ DROPS | 0.70 mg | OPHTHALMIC | NDA | 22 sections |
| bromfenac | Human Prescription Drug Label | 1 | 46708-508 | SOLUTION/ DROPS | 1.04 mg | OPHTHALMIC | ANDA | 22 sections |
| BROMFENAC SODIUM | Human Prescription Drug Label | 1 | 46708-583 | SOLUTION/ DROPS | 0.81 mg | OPHTHALMIC | ANDA | 22 sections |
| BROMSITE 0.075% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49708-754 | SOLUTION/ DROPS | 0.76 mg | OPHTHALMIC | NDA | 23 sections |
| bromfenac 0.075% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49708-755 | SOLUTION/ DROPS | 0.76 mg | OPHTHALMIC | NDA authorized generic | 23 sections |
| bromfenac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-249 | SOLUTION/ DROPS | 1.04 mg | OPHTHALMIC | ANDA | 25 sections |
| Bromday | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50436-6301 | SOLUTION/ DROPS | 0.90 mg | OPHTHALMIC | NDA | 22 sections |
| Bromday | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6301 | SOLUTION/ DROPS | 0.90 mg | OPHTHALMIC | NDA | 22 sections |
| Bromfenac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6343 | SOLUTION/ DROPS | 1.04 mg | OPHTHALMIC | ANDA | 23 sections |
| Bromfenac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1526 | SOLUTION/ DROPS | 0.70 mg | OPHTHALMIC | ANDA | 21 sections |
| Bromfenac Ophthalmic Solution, 0.07% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-1006 | SOLUTION/ DROPS | 0.70 mg | OPHTHALMIC | ANDA | 21 sections |
| Bromfenac Ophthalmic Solution 0.09% | Human Prescription Drug Label | 1 | 62332-508 | SOLUTION/ DROPS | 1.04 mg | OPHTHALMIC | ANDA | 22 sections |
| BROMFENAC SODIUM | Human Prescription Drug Label | 1 | 62332-583 | SOLUTION/ DROPS | 0.81 mg | OPHTHALMIC | ANDA | 22 sections |
| Bromfenac | Human Prescription Drug Label | 1 | 65862-789 | SOLUTION/ DROPS | 0.90 mg | OPHTHALMIC | ANDA | 22 sections |
| BROMFENAC | Human Prescription Drug Label | 1 | 68083-313 | SOLUTION/ DROPS | 0.90 mg | OPHTHALMIC | ANDA | 22 sections |
| bromfenac sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-433 | SOLUTION/ DROPS | 0.81 mg | OPHTHALMIC | ANDA | 21 sections |
| BROMFENAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-434 | SOLUTION/ DROPS | 0.75 mg | OPHTHALMIC | ANDA | 20 sections |
| BROMFENAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-434 | SOLUTION/ DROPS | 0.75 mg | OPHTHALMIC | ANDA | 20 sections |
| Bromfenac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-436 | SOLUTION | 0.90 mg | OPHTHALMIC | ANDA | 22 sections |
| Bromfenac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-436 | SOLUTION | 0.90 mg | OPHTHALMIC | ANDA | 22 sections |
| Pred-Gati-Brom | HUMAN PRESCRIPTION DRUG LABEL | 3 | 70261-504 | SUSPENSION/ DROPS | 0.75 mg | OPHTHALMIC | unapproved drug other | 2 sections |
| Pred-Brom | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70261-505 | SUSPENSION/ DROPS | 0.75 mg | OPHTHALMIC | unapproved drug other | 2 sections |
| Pred-Brom | HUMAN PRESCRIPTION DRUG LABEL | 2 | 71384-505 | SUSPENSION/ DROPS | 0.75 mg | OPHTHALMIC | unapproved drug other | 2 sections |
| Pred Phos - Brom | HUMAN PRESCRIPTION DRUG LABEL | 2 | 71384-552 | SOLUTION/ DROPS | 0.75 mg | OPHTHALMIC | unapproved drug other | 2 sections |
| BROMFENAC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72266-142 | SOLUTION/ DROPS | 0.90 mg | OPHTHALMIC | ANDA | 22 sections |
| Bromfenac | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-649 | SOLUTION/ DROPS | 1.04 mg | OPHTHALMIC | ANDA | 25 sections |
| bromfenac ophthalmic solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75907-093 | SOLUTION/ DROPS | 0.70 mg | OPHTHALMIC | NDA authorized generic | 21 sections |
| bromfenac ophthalmic solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82260-602 | SOLUTION/ DROPS | 0.70 mg | OPHTHALMIC | NDA authorized generic | 21 sections |